• News

    Forxiga receives positive EU CHMP for type I diabetes in adults

    AstraZeneca’s Forxiga (dapagliflozin) has been recommended by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) as an oral adjunct treatment to insulin in adults with type I diabetes. Forxiga is a selective sodium glucose cotransporter-2 (SGLT2) inhibitor, the first oral medicine to receive…